Firmonertinib

small molecule

Identifier: CI-DRUG-00000247
Entity page: /drug/firmonertinib ↗
Edges: 63

Neighbours: 8 cancers1 genes10 trials
Drawn: 19 of 19 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Firmonertinib targets …TARGETS1 of 1
→ targets	EGFR	—	INHIBITOR	—	1	Curated	chembl	graph →
Firmonertinib investigated for …INVESTIGATED_FOR4 of 4
→ investigated for	Lung Non-Small Cell Carcinomasubtype	unknown	3

Firmonertinib investigated in trials for …INVESTIGATED_IN_TRIALSderived6 of 6
→ investigated in trials for	Lung Non-Small Cell Carcinomasubtype 39 trials (28 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	39	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Adenocarcinomasubtype 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Adenocarcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Lung Neoplasm 3 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Lung Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Meningeal Carcinomatosis 3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Meningeal Carcinomatosis	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Brain Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Brain Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Neoplasm of Lung - Multiple Primary Sites 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Neoplasm of Lung - Multiple Primary Sites	1	Observed	clinicaltrials	graph →

Firmonertinib investigated in trials for …INVESTIGATED_IN_TRIALSderived6 of 6

→ investigated in trials for

Lung Non-Small Cell Carcinomasubtype

39 trials (28 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Lung Non-Small Cell Carcinoma

Observed

Firmonertinib studied in …STUDIED_INderived10 of 52show all (up to 200)
→ studied in	NCT07622186Phase 2 · recruiting A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC) · 52 trials list this drug (34 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07185997Phase 3 · recruiting Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations · 52 trials list this drug (34 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05987826Phase 2 · recruiting Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC · 52 trials list this drug (34 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04858958Phase 1 · completed Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation · 52 trials list this drug (34 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05466149Phase 2 · active not recruiting Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion · 52 trials list this drug (34 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06812871Phase 2 · completed High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis · 52 trials list this drug (34 active)	—	—	Meningeal Carcinomatosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT04853342Phase 3 · recruiting To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy · 52 trials list this drug (34 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06956001Phase 3 · recruiting Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation · 52 trials list this drug (34 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06970639Phase 3 · recruiting A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases · 52 trials list this drug (34 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT07482605Phase 2 · not yet recruiting Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion · 52 trials list this drug (34 active)	—	—	Malignant Lung Neoplasm	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths